Ocular Therapeutix (OCUL) Scheduled to Post Earnings on Wednesday

Ocular Therapeutix (NASDAQ:OCUL) is set to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Ocular Therapeutix had a negative return on equity of 165.85% and a negative net margin of 2,956.91%. The business had revenue of $0.49 million during the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ OCUL opened at $4.82 on Friday. The company has a debt-to-equity ratio of 2.17, a current ratio of 9.19 and a quick ratio of 9.16. The stock has a 50 day simple moving average of $4.70. Ocular Therapeutix has a 12 month low of $2.35 and a 12 month high of $7.31. The company has a market cap of $199.19 million, a P/E ratio of -3.07 and a beta of 2.25.

In other news, CEO Antony C. Mattessich purchased 40,000 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were acquired at an average price of $2.81 per share, for a total transaction of $112,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 97,900 shares of the company’s stock, valued at $275,099. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael H. Goldstein acquired 12,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was bought at an average price of $2.51 per share, for a total transaction of $30,120.00. Following the purchase, the insider now owns 25,686 shares in the company, valued at approximately $64,471.86. The disclosure for this purchase can be found here. Insiders have bought 229,248 shares of company stock worth $669,811 in the last 90 days. 16.10% of the stock is owned by company insiders.

OCUL has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Wednesday, July 24th. ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Thursday. Raymond James downgraded shares of Ocular Therapeutix from a “strong-buy” rating to an “outperform” rating and dropped their target price for the stock from $11.00 to $5.00 in a report on Tuesday, May 21st. HC Wainwright set a $9.00 target price on shares of Ocular Therapeutix and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Finally, Piper Jaffray Companies set a $8.00 price target on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Friday, July 26th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $9.18.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Read More: The Role of a Fiduciary and Individual Investors

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.